Benzinga | Nov 3, 2021 09:20AM EDT

RBC Capital Maintains Outperform on Exelixis, Lowers Price Target to $31

RBC Capital analyst Kennen MacKay maintains Exelixis (NASDAQ:EXEL) with a Outperform and lowers the price target from $32 to $31.